Number of patients (%) | 21 (100) |
Sex, number (%) | |
 Male | 14 (66.7) |
 Female | 7 (33.3) |
Age (median range) | 12 (2–19) |
 Primary pathology, number (%) | |
 Cerebral palsy | 7 (33,3) |
 Encephalopathy | 5 (23,8) |
 Suprabulbar paralysis | 1 (4,8) |
 SMA | 2 (9,5) |
 Herpetic encephalitis | 1 (4,8) |
 Generalized dyspraxia | 1 (4,8) |
 Anorexia | 1 (4,8) |
 Genetic syndromes | 3 (14,3) |
Gross Motor Function Classification System, number (%) | |
 GMFCS I | 0 (0) |
 GMFCS II | 2 (9,5) |
 GMFCS III | 2 (9,5) |
 GMFCS IV | 6 (23,9) |
 GMFCS V | 11 (57,1) |
PPI administration, number (%) | |
 Yes | 13 (61,9) |
 No | 8 (39,1) |
PEG, number (%) | |
 Yes | 10 (47,6) |
 No | 11 (52,4) |
Fundoplication, number (%) | |
 Yes | 6 (28,6) |
 No | 15 (71,4) |
Tracheostomy, number (%) | |
 Yes | 4 (19) |
 No | 17 (81) |
Current scopolamine therapy, number (%) | |
 Yes | 2 (9,5) |
 No | 19 (90,5) |
Antiepileptic treatment, number (%) | |
 Yes | 13 (61,9) |
 No | 8 (39,1) |
Other drugs, number (%) | |
 Yes | 15 (71,4) |
 No | 6 (28,6) |
Past therapies for drooling, number (%) | |
 Scopolamine | 3 (14,3) |
 Botulinum toxin | 5 (23,8) |